Fig. 7: The impact of IL-17A on septic ALI.

a Representative FCM plots and frequency of AMs, b IMs, and c neutrophils in the lung of septic mice treated with IL-17A-expressing recombinant adenovirus (Adv-IL-17A) or control Adv (Adv-Ctrl) (n = 6 for CLP + Adv-Ctrl, 7 for CLP + Adv-IL-17A). d, e Representative FCM plots and percentage of CD86 and CD206 markers in AMs and IMs (n = 6). f Representative H&E sections of lung and histological injury scores in septic mice treated with Adv-Ctrl or Adv-IL-17A (n = 7). 20×, Scale bar = 100 μm. 40×, Scale bar = 50 μm. g, h Representative FCM plots and frequency of AMs and neutrophils in the lung of septic mice treated with adenovirus expressing IL-17A- shRNA (Adv-shRNA (IL-17A)) or adenovirus-negative control (Adv-NC) (n = 6). i Representative H&E sections of lung and histological injury scores. 20×, Scale bar = 100 μm. 40X, Scale bar = 50 μm. j Representative images and semi-quantitative analysis of NETs formation in the lung detected by immunofluorescence staining with Cit-H3 and MPO (n = 6). 20X, Scale bar = 50 μm. 40×, Scale bar = 25 μm. k The protein level of IL-6 and TNF-α in the BALF in septic mice treated with Adv-IL-17A (or Adv-Ctrl) or Adv-shRNA (IL-17A) (or Adv-NC) (n = 8 for IL-6 in CLP + Adv-Ctrl and CLP + Adv-NC, TNF-α in CLP + Adv-IL-17A and CLP + Adv-Ctrl, 7 for IL-6 in CLP + Adv-IL-17A and CLP + Adv-shRNA (IL-17A), TNF-α in CLP + Adv-Ctrl and CLP + Adv-shRNA (IL-17A)). l Kaplan–Meier analysis of survival in septic mice treated with Adv-IL-17A (or Adv-Ctrl) or Adv-shRNA (IL-17A) (or Adv-NC) (n = 20). Data are shown as mean ± SD. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, ^****P < 0.0001. P values were calculated using two-sided Student’s unpaired t-test (a–k), and the Log-rank (Mantel–Cox) test (l). Source data and exact P values are provided as a Source Data file.